AGMB Healthcare

AgomAb Therapeutics NV

$6.85+1.93%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Belgium
Market cap: 337.3M USD
Enterprise value: 53.6M USD
Full-time employees: 62

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #932 of 1,157 fully scored healthcare companies (bottom 20%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Not profitable yet. Reported a loss in the 12 months to December 2025.
AgomAb Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Financials may be out of date. Latest financial period ended 10 months ago.
The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.
Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
AgomAb Therapeutics has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

33/ 100

Oct 5 33 → Nov 4 33

Valuation

Is the price right?

0/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-10.4%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · EUR→USD at the current rateNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-138.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 months · EUR→USD convertedNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield21.8%

SEC filings (IFRS mapped) · latest balance sheet · EUR→USD at the current rateReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

12/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-40.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -7.89Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-105.3%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -10.95Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-47.8%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio6.52×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score 2.84Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about AgomAb Therapeutics

Is AgomAb Therapeutics getting weaker?: A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 33/100 since Oct 28, 2026.
How is AgomAb Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -10.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -10.4% vs peers 1.5% (weaker than 100% of peers).
Is AgomAb Therapeutics growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is AgomAb Therapeutics?: Less profitable than most of its peers. Profitability scores 12/100 against 1,393 healthcare peers. Return on invested capital -105.3% vs a peer median of 4.7% (weaker than 93% of peers).Return on invested capital -105.3% vs peers 4.7% (weaker than 93% of peers).
How risky is AgomAb Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 94% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 94% of peers). A relative measure, not a bankruptcy probability.

Financials

Fiscal years from SEC annual filings · change vs the prior year · amounts in EUR, as reported

Key ratios	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	—	-22.4%	-40.7%	▼ 18 pts
Return on equity (ROE)	-7.5%	-24.6%	-47.8%	▼ 23 pts
Current ratio	—	19.05×	6.52×	▼ 66%
Interest coverage	-1006.13×	-716.73×	-987.92×	▼ 38%

AGMB price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #932 of 1,157 fully scored healthcare companies (bottom 20%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Not profitable yet. Reported a loss in the 12 months to December 2025.

AgomAb Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Financials may be out of date. Latest financial period ended 10 months ago.

The latest financial period we have ended 10 months ago, so the scores may not reflect recent results.

Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.

AgomAb Therapeutics has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about AgomAb Therapeutics

Is AgomAb Therapeutics getting weaker?

A comparison of its latest SEC filing with the previous one isn't available yet. Its overall score is unchanged at 33/100 since Oct 28, 2026.

How is AgomAb Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -10.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -10.4% vs peers 1.5% (weaker than 100% of peers).

Is AgomAb Therapeutics growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is AgomAb Therapeutics?

Less profitable than most of its peers. Profitability scores 12/100 against 1,393 healthcare peers. Return on invested capital -105.3% vs a peer median of 4.7% (weaker than 93% of peers).Return on invested capital -105.3% vs peers 4.7% (weaker than 93% of peers).

How risky is AgomAb Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 94% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 94% of peers). A relative measure, not a bankruptcy probability.

Key ratios

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

—

-22.4%

-40.7%

▼ 18 pts

Return on equity (ROE)

-7.5%

-24.6%

-47.8%

▼ 23 pts

Current ratio

—

19.05×

6.52×

▼ 66%

Interest coverage

-1006.13×

-716.73×

-987.92×

▼ 38%